Rituximab for rheumatoid arthritis refractory to anti???tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis & Rheumatism, vol.64, issue.9, pp.2793-806, 2006. ,
DOI : 10.1002/art.22025
Efficacy of B-Cell???Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis, New England Journal of Medicine, vol.350, issue.25, pp.2572-81, 2004. ,
DOI : 10.1056/NEJMoa032534
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis, Arthritis & Rheumatism, vol.46, issue.10, pp.2993-3002, 2008. ,
DOI : 10.1002/art.23902
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.52, issue.2, pp.613-633, 2006. ,
DOI : 10.1002/art.21617
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response, Arthritis Research & Therapy, vol.11, issue.4, p.131, 2009. ,
DOI : 10.1186/ar2798
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis, Arthritis Research & Therapy, vol.11, issue.4, p.123, 2009. ,
DOI : 10.1186/ar2789
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis, Arthritis & Rheumatism, vol.174, issue.8, pp.2377-86, 2006. ,
DOI : 10.1002/art.22019
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study, Arthritis & Rheumatism, vol.62, issue.Suppl, pp.933-941, 2011. ,
DOI : 10.1002/art.30233
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis, Rheumatology, vol.48, issue.12, pp.1557-1566, 2009. ,
DOI : 10.1093/rheumatology/kep314
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis, Arthritis & Rheumatism, vol.105, issue.8, pp.2146-54, 2003. ,
DOI : 10.1002/art.11181
Rituximab-Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical Response, Arthritis & Rheumatism, vol.58, issue.Suppl 1, pp.2783-90, 2013. ,
DOI : 10.1002/art.38107
Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab, Rheumatology International, vol.4, issue.9, pp.1571-1574, 2015. ,
DOI : 10.1007/s00296-015-3295-0
Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, Arthritis & Rheumatism, vol.38, issue.1, pp.34-40, 1996. ,
DOI : 10.1002/art.1780390105
Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study, The Journal of Rheumatology, vol.39, issue.12, pp.2238-2284, 2012. ,
DOI : 10.3899/jrheum.120573
Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment, Arthritis & Rheumatism, vol.33, issue.6, pp.1566-75, 2008. ,
DOI : 10.1002/art.23473